Drug
Efgartigimod Ph20 Via Pfs
Efgartigimod Ph20 Via Pfs: highest development phase Phase 1, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efgartigimod PH20 SC via PFS NCT07782775 | Phase 1 | Healthy Volunteer |
Latest
No recent events.
Follow Efgartigimod Ph20 Via Pfs on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.